Trial Profile
An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa (RO6874281), an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Simlukafusp alfa (Primary) ; Gemcitabine; Vinorelbine; Vinorelbine
- Indications Cervical cancer; Gilbert's disease; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Roche
- 20 Feb 2023 Status changed from completed to discontinued. The Sponsor discontinued the development of Simlukafusp alfa due to portfolio prioritization, not due to any safety, efficacy, or quality issues.
- 18 Feb 2022 Status changed from active, no longer recruiting to completed.
- 20 Jan 2022 This trial is completed in Poland according to European Clinical Trials Database record.